Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • ATG4B Nuclear Translocation Links Energy Deficiency to AML P

    2026-07-31

    Energy Deficiency, ATG4B Nuclear Translocation, and DNA Repair in AML

    Study Background and Research Question

    Cellular metabolism and genomic stability are fundamental to cell survival and function, with their dysregulation implicated in a range of pathologies including cancer and aging. While the influence of metabolism on DNA repair has been recognized—through effects on chromatin state, nucleotide synthesis, and reactive oxygen species (ROS) generation—the precise molecular mechanisms linking metabolic stress to genomic instability remain poorly defined. Acute myeloid leukemia (AML), characterized by high rates of mutation and metabolic reprogramming, provides an ideal system to investigate these connections. The central research question in the reference study is: How does cellular energy deficiency mechanistically impair DNA repair, and what are the consequences for AML progression?

    Key Innovation from the Reference Study

    The pivotal innovation of this study lies in identifying ATG4B nuclear translocation as a direct molecular link between energy deficiency and impaired DNA repair in AML. Specifically, under conditions of metabolic stress, ATG4B translocates from the cytoplasm to the nucleus, where it physically interacts with PRMT1, a methyltransferase critical for DNA repair. This nuclear action of ATG4B inhibits PRMT1-dependent methylation of MRE11, a central component of the DNA damage response machinery. As a result, DNA repair capacity is compromised, driving genomic instability and promoting leukemic progression. This mechanism represents a significant advance in understanding how metabolic disruptions translate into genomic defects in cancer cells.

    Methods and Experimental Design Insights

    The authors employed an integrated approach combining molecular biology, cellular assays, and in vivo disease models. Key methodologies included:

    • Induction of energy deficiency in AML cell lines and primary patient-derived cells using nutrient deprivation and metabolic inhibitors.
    • Subcellular fractionation and immunofluorescence microscopy to track ATG4B localization under energy stress.
    • Co-immunoprecipitation and proximity ligation assays to probe the interaction between ATG4B and PRMT1 in the nuclear compartment.
    • Assessment of MRE11 methylation status via immunoblotting and methylation-specific antibodies.
    • Functional analysis of DNA repair capacity using γH2AX foci formation, comet assays, and measurement of mutation burden.
    • AML progression evaluated in both MLLT3-KMT2A overexpression mouse models and patient-derived xenografts, with and without pharmacological or genetic inhibition of ATG4B.

    This multifaceted design enabled the authors to dissect both the biochemical pathway and its functional consequences in relevant disease contexts.

    Core Findings and Why They Matter

    The study reports several interlinked findings with broad implications:

    • Energy deficiency triggers ATG4B nuclear translocation: Under conditions of metabolic stress, ATG4B moves from the cytoplasm to the nucleus in AML cells.
    • ATG4B-PRMT1 interaction inhibits MRE11 methylation: Nuclear ATG4B binds PRMT1, reducing PRMT1-mediated methylation of MRE11, an event critical for efficient DNA repair.
    • DNA repair is compromised: Loss of MRE11 methylation leads to defective DNA damage response, increased accumulation of DNA lesions, and higher mutation rates.
    • AML progression is accelerated: These defects are particularly pronounced in both patient-derived AML cells and in MLLT3-KMT2A-driven mouse models, resulting in faster leukemic progression and reduced survival.
    • ATG4B inhibition restores DNA repair and delays leukemia: Genetic or pharmacological inhibition of ATG4B reverses DNA repair defects, lowers mutation burden, suppresses cell proliferation, and prolongs survival in AML models.

    Together, these results position ATG4B as a key mediator of the metabolic-genomic axis in cancer, suggesting new avenues for therapeutic intervention that target metabolic vulnerabilities to restore genome maintenance.

    Comparison with Existing Internal Articles

    Several recent articles provide complementary perspectives on these findings. For instance, one internal study also highlights the role of ATG4B in mediating energy deficiency-induced DNA repair defects in AML, reinforcing the robustness of this mechanistic insight. Another article, focused on metabolic-genomic crosstalk, contextualizes the role of PRMT1-MRE11 signaling in leukemic progression, aligning with the reference study’s emphasis on the importance of post-translational modifications in DNA repair regulation. These complementary resources broaden the understanding of how targeting metabolic stress responses may be leveraged in antifungal drug development or fungal infection models, particularly where DNA repair and cell integrity intersect.

    Furthermore, recent literature on antifungal therapy, such as mechanistic analyses of Tioconazole, demonstrates how disrupting ergosterol biosynthesis can induce stress responses analogous to those seen in metabolic-genomic crosstalk in cancer. This connection underscores the broader relevance of studying stress-induced nuclear signaling beyond oncology.

    Limitations and Transferability

    While the reference study provides compelling evidence for the role of ATG4B in linking energy deficiency to DNA repair inhibition in AML, several limitations warrant consideration. First, although the mouse and patient-derived xenograft models recapitulate key features of human AML, the generalizability of these findings to other cancer types or to non-malignant cells remains to be established. Second, the study’s reliance on in vitro energy deficiency models, while informative, may not fully capture the complexity of metabolic stress in vivo. Finally, the therapeutic potential of ATG4B inhibition requires further validation in preclinical and clinical settings, particularly concerning specificity and possible off-target effects.

    Nevertheless, the mechanistic clarity achieved by precisely mapping the ATG4B–PRMT1–MRE11 axis provides a strong foundation for the rational design of metabolic interventions for genomic instability disorders.

    Protocol Parameters

    • Induction of energy deficiency: Serum and glucose deprivation for 12–24 hours in AML cell lines to mimic metabolic stress conditions.
    • Subcellular localization assays: Immunofluorescence staining for ATG4B, with DAPI nuclear counterstain; quantify nuclear/cytoplasmic ratio.
    • Co-immunoprecipitation: Nuclear extracts prepared under non-denaturing conditions; ATG4B and PRMT1 antibodies used for reciprocal pulldown and immunoblotting.
    • MRE11 methylation detection: Use of methylation-specific antibodies following nuclear protein isolation; validate by loss-of-function PRMT1 knockdown.
    • Assessment of DNA repair capacity: γH2AX foci quantification post-ionizing radiation; comet assay for direct DNA strand break analysis.
    • AML in vivo modeling: Transplantation of MLLT3-KMT2A-transduced bone marrow cells into syngeneic mice; disease progression tracked by peripheral blood counts, survival analysis, and histopathology.
    • ATG4B inhibition: Genetic (shRNA/CRISPR) or small-molecule inhibitor administration, with dosing based on cell viability and toxicity pilot experiments.

    Why this cross-domain matters, maturity, and limitations

    The intersection between metabolic stress responses and genomic maintenance, as demonstrated in AML, has implications for other fields where cellular energy sensing is critical—such as antifungal drug development. Drugs targeting metabolic pathways, including those that disrupt ergosterol biosynthesis in fungi (as seen with azole antifungal mechanisms), may induce stress responses that impact genome stability in model organisms. However, direct translation of the ATG4B–PRMT1–MRE11 axis to fungal systems or other disease contexts requires careful experimental validation, as the molecular players and regulatory networks may differ.

    Research Support Resources

    For researchers developing antifungal infection models or investigating the interplay between metabolic stress and genomic maintenance, reliable reagents are essential. Tioconazole (SKU B2051) is a well-characterized antifungal medication that acts by inhibiting fungal cytochrome P450 enzymes, thereby disrupting the ergosterol biosynthesis pathway essential for fungal cell membrane integrity. According to the product information, Tioconazole is supplied at high purity, suitable for in vitro antifungal assays and research into antifungal drug development, including studies that require robust modeling of fungal cell membrane stress responses. Solutions are best prepared fresh and stored at -20°C to maintain compound stability. For further procedural guidance, researchers may consult scenario-driven best practices as summarized in recent resources focused on cell viability and fungal infection protocols.